Influence of NRLN Metastasis as a Prognostic Factor in Metastatic Prostate Cancer Patients 679 of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 2008;14:1599-602. 5. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following con- servative management of clinically localized prostate cancer. JAMA 2005;293:2095-101. 6. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9. 7. Epstein JI. Pathology of prostatic neoplasia. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell’s urology. 10th ed. Philadelphia: Saunders; 2012. p. 2726-34. 8. Corriere JN Jr, Cornog JL, Murphy JJ. Prognosis in patients with carcinoma of the prostate. Cancer 1970;25:911-8. 9. Furuya Y, Akakura K, Akimoto S, Ito H. Prognosis of patients with prostate carcinoma presenting as nonregional lymph node metastases. Urol Int 1998;61:17-21. 10. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64. 11. Harmer MH. TNM classification of malignant tumours. 3rd ed. Geneva: International Union against Cancer; 1978. 12. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic pros- tate cancer based on EOD on initial bone scan. Cancer 1988;61:195-202. 13. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22:537-56. 14. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11:5223-32. 15. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34:187-220. 16. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106:1624-33. 17. Weiss L. Mechanisms of metastatic patterns. In: Weiss L, editor. Principles of metastasis. Orlando: Academic Press Inc.; 1985. p. 200-56. 18. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8. 19. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;133:571-3. 20. Van't Veer LJ, Weigelt B. Road map to metastasis. Nat Med 2003;9:999-1000. 21. Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, Eschrich S, et al. Multi-platform, multi-site, microarray-based human tu- mor classification. Am J Pathol 2004;164:9-16. 22. Berry WR, Laszlo J, Cox E, Walker A, Paulson D. Prognostic fac- tors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 1979;44:763-75. 23. Emrich LJ, Priore RL, Murphy GP, Brady MF. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985;45:5173-9. 24. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leu- kemia group B 9182 study. J Clin Oncol 1999;17:2506-13. Korean J Urol 2012;53:673-679